Everything tagged "healthcare" across research, earnings, and macro.
70 articles
Danaher is emerging from a mixed-cycle recovery with improving bioprocessing orders, steady recurring revenue, and stronger EPS guidance. The stock looks attractive on a forward basis, but valuation still argues for buying on weakness.
Summit Therapeutics is a high-upside, high-volatility oncology story centered on ivonescimab and a November 2026 FDA decision. The clinical data are compelling, but the stock already prices in a lot of success.
Intuitive Surgical is still compounding through mid-teens procedure growth, rising da Vinci 5 adoption, and a highly recurring revenue mix. The stock looks like a quality-growth name with strong execution, but valuation remains rich.
Elevance Health is a high-quality managed care franchise taking a deliberate earnings reset in 2026 to protect long-term margins. The stock looks reasonably valued versus its earnings power, with a path to stronger growth in 2027.
Elevance Health Inc. (ELV) gains 2.3% after earnings meets estimates, with investors reacting positively to the company’s latest quarterly results and outlook.
UnitedHealth Group Incorporated (UNH) rises after a meet-quarter that looked better than feared. This deep-dive earnings analysis examines revenue stability, Optum Health margin repair, medical cost trends, and management’s 2026-2027 outlook to explain why investors rewarded signs of operational recovery.
UnitedHealth is still a healthcare giant, but 2025 exposed a sharp margin reset driven by medical cost inflation and OptumHealth weakness. The stock looks like a Buy for medium-term investors if management can keep the 2026 repair on track.
UnitedHealth Group Incorporated (UNH) rises 9.1% after earnings meets expectations, lifting shares as investors react to the latest quarterly results and outlook.
Alcon is a steady eye-care compounder with recurring revenue, new product momentum, and a disciplined balance sheet. The stock looks constructive, but not deeply cheap, after solid FY2025 growth and a still-elevated valuation.
Abbott Laboratories is a diversified healthcare compounder with improving growth across medical devices, diagnostics, nutrition, and emerging-market pharmaceuticals. The stock looks high quality but fairly valued, making it more attractive on pullbacks than at current levels.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator